Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, defines oligometastatic lung cancer and describes the recent trend toward the use of stereotactic body radiation therapy to treat it.
Video Library
Search the Video Library
Video Language
Filter by Cancer Type:
Displaying Results 16 - 30 of 72
Dr. Nathan Pennell, Cleveland Clinic, discusses acquired resistance to Xalkori in ALK-positive patients, and second generation inhibitors designed to overcome that resistance, such as Zykadia and alectinib.
Dr. Nathan Pennell, Cleveland Clinic, describes treatment of NSCLC patients with HER2 mutations using agents such as Gilotrif or Herceptin.
For our 4th video in the GRACE Spanish Lung Cancer Library, Antonio Calles, MD joined GRACE to discuss what the role of Avastin (bevacizumab) is in treating advanced NSCLC today.
Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, describes the types of situations in which local therapy is appropriate for treating limited acquired resistance.
Dr. H. Jack West, Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, President and CEO of GRACE offers updates to our Lung Cancer Video Library. In this video, Dr. West discusses chemotherapy and immunotherapy combinations in advanced squamous non-small cell lung cancer. We thank
For our 16th video in the GRACE Spanish Lung Cancer Library, Brian Hunis, MD joined GRACE to discuss ALK rearrangements, what they are who has them.
For our 17th video in the GRACE Spanish Lung Cancer Library, Brian Hunis, MD joined GRACE to discuss first line therapy for NSCLC patients that have anaplastic lymphoma kinase (ALK) positive.
For our 18th video in the GRACE Spanish Lung Cancer Library, Brian Hunis, MD joined GRACE to discuss acquired resistance to targeted therapies: biology and different clinical patterns.
For our 19th video in the GRACE Spanish Lung Cancer Library, Dr. Brian Hunis, joined GRACE to discuss the basics of Lung Cancer for Spanish-speaking patients and caregivers. In this video Dr. Hunis discusses second line therapy for NSCLC patients who are ALK positive.
Nathan Pennell, MD, PhD , Director of Lung Cancer Medical Oncology at the Cleveland Clinic Taussig Cancer Center in Cleveland Ohio discusses liquid biopsies for EGFR T790 non-small cell lung cancer (NSCLC). We would like to thank the following companies for their support of this program
Nathan Pennell, MD, PhD , Director of Lung Cancer Medical Oncology at the Cleveland Clinic Taussig Cancer Center in Cleveland Ohio discusses Liquid Biopsies for Broad Genomic Testing in Lung Cancer. We would like to thank the following companies for their support of this program
Nathan Pennell, MD, PhD, Director of Lung Cancer Medical Oncology at the Cleveland Clinic Taussig Cancer Center in Cleveland Ohio discusses new options in acquired resistance for ALK positive non-small cell lung cancer (NSCLC).
Dr. Alice Shaw joined GRACE to discuss patterns of resistance in ALK positive non small cell lung cancer.
Dr. Alice Shaw joined GRACE to discuss the changing landscape of first-line treatment of ALK-positive advanced non-small cell lung cancer.